

10/3/03

PTO/SB/08 (08-00)
2. OMB 0651-0031
U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office
OMB control

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 3, 2003 (use as many sheets as necessary)		Complete if Known	
Application Number	Unassigned 15/6	7,227	
Filing Date	10/03/2003		
First Named Inventor	Hiroaki ITO et al.		
Group Art Unit	1646		
Examiner Name	Unassigned <i>Penna</i>		
Attorney Docket Number	05346E-0365		
Sheet <u>1</u>	of <u>2</u>		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Page, Columns, Lines, here Relevant Pages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Page, Columns, Lines, here Relevant Pages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
PM	A1	WO	96/40966	A1	Private Biologicals Corporation	12/19/1996	
	A2	JP	7-324097			12/12/1995	
	A3	JP	8-311098			11/26/1996	
	A4	JP	8-245414			09/24/1996	
	A5	JP	9-235276			09/09/1997	
	A6	JP	8-99996			04/18/1996	
	A7	JP	8-50829			09/03/1996	
	A8	WO	96/40966		WO 96/40966	12/19/1996	
	A9	WO	98/38481		The Board of Regents of the University of Oklahoma	12/05/1996	
	A10	EP	0 811 384		SEIYAKI et al.	12/10/1997	
	A11	WO	99/64069		Ophidian Pharmaceuticals, Inc.	12/16/1999	

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume- issue number(s), publisher, city and/or country where published.				T ⁶
PM ↓	A12	POWRIE et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease In mice Reconstituted With CD45Rbhi CD4+ T Cells", Immunity, Vol. 1:553-562, (1994).				
	A13	TAKAGI et al., "Blockage Of Interleukin-6 Receptor Ameliorates Joint Disease In Murine Collagen-Induced Arthritis", Arthritis Rheumatism, Vol. 41(2):2117-2121, (1998).				
	A14	MITSUYAMA et al., "Soluble Interleukin-6 Receptors In Inflammatory Bowel Disease; Relation To Circulating Interleukin-6", Gut, Vol. 36:45-49, (1995).				
	A15	VAN DULLEMEN et al., "Treatment Of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)", Gastroenterology, Vol. 109:129-135, (1995).				
	A16	SASAJIMA et al., "Changes in Serum Cytokine Profile During Treatment of Ulcerative Colitis", Journal of Gastroenterology and Hepatology, December 1997, pages A274, vol. 12, no. SUPPL., XP01105732.				

Examiner Signature	<i>Penna</i>	Date Considered	10/21/06
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16, if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.